[{"id":"da41551a-8725-4ada-8cf7-99ed7c4f6360","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739111","created_at":"2022-06-29T09:02:24.631Z","updated_at":"2024-07-02T16:36:34.938Z","phase":"Phase 1","brief_title":"An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor","source_id_and_acronym":"NCT04739111","lead_sponsor":"Dragonboat Biopharmaceutical Company Limited","biomarkers":" RAS","pipe":"","alterations":" ","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BC001 (cetuximab biosimilar) • lesabelimab (BC003)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 01/29/2021","start_date":" 01/29/2021","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2021-02-08"},{"id":"9aab6e3e-4ea5-4f7e-8b27-9b27341ac1de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04151810","created_at":"2021-01-18T20:15:59.672Z","updated_at":"2024-07-02T16:36:53.959Z","phase":"Phase 1","brief_title":"Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04151810","lead_sponsor":"Dragonboat Biopharmaceutical Company Limited","biomarkers":" BRAF • RAS • CUX1","pipe":"","alterations":" ","tags":["BRAF • RAS • CUX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BC001 (cetuximab biosimilar)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 12/30/2019","start_date":" 12/30/2019","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2019-11-05"},{"id":"71f19e4c-e061-4785-8b02-3310ad3641cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03491709","created_at":"2021-01-18T17:11:47.995Z","updated_at":"2024-07-02T16:36:54.076Z","phase":"Phase 1","brief_title":"A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC","source_id_and_acronym":"NCT03491709","lead_sponsor":"Dragonboat Biopharmaceutical Company Limited","biomarkers":" CUX1","pipe":"","alterations":" ","tags":["CUX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • BC001 (cetuximab biosimilar)"],"overall_status":"Unknown status","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 09/17/2019","primary_completion_date":" 09/17/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-10-31"}]